LYRM2

Across TCGA pan-cancer cohorts, LYRM2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LYRM2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LYRM2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LYRM2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where LYRM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	1.000	0.878	.013	14	view →
PDAC	OS	Median	III,IV	1.000	0.537	.008	10	view →
CCRCC	DFS	Quartile	II,III,IV	0.406	0.791	.006	6	view →
HNSC	OS	Median	All	0.347	0.887	.046	4	view →
LUAD	DFS	Median	III,IV	0.732	0.325	.028	3	view →
GBM	DFS	Quartile	All	0.465	0.296	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LYRM2–LSCC (OS)

Open the LSCC breakdown →